From the Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, New York.
Dr. Mansouri reports no conflict of interest, but her contribution was supported by the Geoffrey Dowling Fellowship, a grant from the British Association of Dermatologists (United Kingdom). Dr. Goldenberg is a consultant and speaker for AbbVie Inc, Celgene Corporation, and Novartis Corporation. He also is a consultant for Amgen Inc, Janssen Biotech Inc, and Pfizer Inc.
Correspondence: Gary Goldenberg, MD, 5 E 98th St, 5th Floor, New York, NY 10029-6574 (garygoldenbergmd@gmail.com).
Another Jak inhibitor under investigationfor the treatment of psoriasis is ruxolitinib, an inhibitor of Jak1 and Jak2, which has been primarily studied as a topical agent for milder cases of the disease.28
Conclusion
Many new drugs are currently on the horizon and will increase our armamentarium for treating psoriasis. Some of these agents promise greater levels of efficacy than currently used therapies. Although this review focuses on systemic agents, there also are a number of topical formulations in the pipeline. These new agents will certainly increase our options when choosing the most suitable treatment for a patient with psoriasis, but safety will remain a primary concern, and time and experience will tell whether efficacy outweighs any potential side effects.
